171 related articles for article (PubMed ID: 35842871)
21. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
[TBL] [Abstract][Full Text] [Related]
24. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.
Elshafeey N; Kotrotsou A; Hassan A; Elshafei N; Hassan I; Ahmed S; Abrol S; Agarwal A; El Salek K; Bergamaschi S; Acharya J; Moron FE; Law M; Fuller GN; Huse JT; Zinn PO; Colen RR
Nat Commun; 2019 Jul; 10(1):3170. PubMed ID: 31320621
[TBL] [Abstract][Full Text] [Related]
25. Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study.
Blakstad H; Mendoza Mireles EE; Heggebø LC; Magelssen H; Sprauten M; Johannesen TB; Vik-Mo EO; Leske H; Niehusmann P; Skogen K; Helseth E; Emblem KE; Brandal P
Neurooncol Pract; 2024 Feb; 11(1):36-45. PubMed ID: 38222046
[TBL] [Abstract][Full Text] [Related]
26. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
27. A deep learning model for discriminating true progression from pseudoprogression in glioblastoma patients.
Moassefi M; Faghani S; Conte GM; Kowalchuk RO; Vahdati S; Crompton DJ; Perez-Vega C; Cabreja RAD; Vora SA; Quiñones-Hinojosa A; Parney IF; Trifiletti DM; Erickson BJ
J Neurooncol; 2022 Sep; 159(2):447-455. PubMed ID: 35852738
[TBL] [Abstract][Full Text] [Related]
28. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.
Radbruch A; Fladt J; Kickingereder P; Wiestler B; Nowosielski M; Bäumer P; Schlemmer HP; Wick A; Heiland S; Wick W; Bendszus M
Neuro Oncol; 2015 Jan; 17(1):151-9. PubMed ID: 25038253
[TBL] [Abstract][Full Text] [Related]
29. Differentiation of progressive disease from pseudoprogression using MRI histogram analysis in patients with treated glioblastoma.
Yildirim M; Baykara M
Acta Neurol Belg; 2022 Apr; 122(2):363-368. PubMed ID: 33555560
[TBL] [Abstract][Full Text] [Related]
30. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
31. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
[TBL] [Abstract][Full Text] [Related]
32. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
[TBL] [Abstract][Full Text] [Related]
33. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
[TBL] [Abstract][Full Text] [Related]
34. Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Roldán GB; Scott JN; McIntyre JB; Dharmawardene M; de Robles PA; Magliocco AM; Yan ES; Parney IF; Forsyth PA; Cairncross JG; Hamilton MG; Easaw JC
Can J Neurol Sci; 2009 Sep; 36(5):617-22. PubMed ID: 19831132
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Eur Radiol; 2018 Jun; 28(6):2628-2638. PubMed ID: 29374321
[TBL] [Abstract][Full Text] [Related]
36. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma.
Chakhoyan A; Woodworth DC; Harris RJ; Lai A; Nghiemphu PL; Liau LM; Pope WB; Cloughesy TF; Ellingson BM
J Neurooncol; 2018 Sep; 139(3):651-659. PubMed ID: 29855771
[TBL] [Abstract][Full Text] [Related]
37. Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation.
Chan RW; Chen H; Myrehaug S; Atenafu EG; Stanisz GJ; Stewart J; Maralani PJ; Chan AKM; Daghighi S; Ruschin M; Das S; Perry J; Czarnota GJ; Sahgal A; Lau AZ
J Neurooncol; 2021 Jan; 151(2):267-278. PubMed ID: 33196965
[TBL] [Abstract][Full Text] [Related]
38. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
39. DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet.
Li M; Tang H; Chan MD; Zhou X; Qian X
Med Phys; 2020 Mar; 47(3):1139-1150. PubMed ID: 31885094
[TBL] [Abstract][Full Text] [Related]
40. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
